Elevai Labs Inc (ELAB) News

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation

EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1...

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

Elevai Skincare Expands into Hair Care with Cutting-Edge Scalp and Hair Health System.Root Renewal System...

Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division

Skincare Division Achieves New Sales Milestone, Enters Holiday Season with Strong MomentumStrategic...

Form 8-K - Current report

Form 8-K - Current report

Form DEFR14C - Revised information statement materials, definitive

Form DEFR14C - Revised information statement materials, definitive

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (Elevai" or the...

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the...

Form 8-K - Current report

Form DEF 14C - Other definitive information statements

Form DEF 14C - Other definitive information statements

CORRECTION - Elevai Labs Inc.

NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc...

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources...